Supply for Research, Practice and the Aesthetic Service
Sports medicine practices take part in sponsored studies of cell-free and perinatal biologics, run shockwave services, and often add an aesthetic line. ExaVeyra supplies each of those under its own documentation, and clinical decisions stay with your licensed team.
Exosome material, Wharton’s jelly and MSC products for laboratory research and sponsor-held IND studies, subject to the manufacturer’s authorization.
A certificate of analysis for every lot, the characterization method behind each figure, and chain-of-custody records for the study file.
Biologics ship frozen on dry ice by overnight shipping with a temperature record, and arrival can take 1 to 3 business days.
PhysioPRO extracorporeal shockwave units for licensed practices, sold for the intended use in the manufacturer’s labeling.
Dispensed by our 503A pharmacy partner on a patient-specific prescription, where the pharmacy holds a license for the destination state.
For practices that run an aesthetic service: exosome material for topical aesthetic use on intact or healed skin, as labeled by the manufacturer.
Regulatory notice
Exosome material. No exosome product is approved, cleared or licensed by the FDA for any use in humans, and statements on this site have not been evaluated by the FDA. Exosome material is supplied to NPI-verified licensed practitioners for topical aesthetic use on the skin surface, including after procedures, as labeled by the manufacturer, and for laboratory research and clinical research conducted under an FDA investigational new drug application. It is not supplied for injection, infusion, inhalation, intranasal, ophthalmic or any other route into the body, and it is not intended to diagnose, treat, cure, mitigate or prevent any disease. Whether, how and in what setting it is used, and whether that use complies with scope of practice and state law, is the licensed practitioner’s responsibility. ExaVeyra Sciences is a supplier: it does not provide medical care, does not consult with patients and takes no part in clinical decisions. Research summaries describe published studies and are not claims about any product.
Human cell and tissue products. Mesenchymal stem cell material, from a registered tissue bank operating under 21 CFR Part 1271, is supplied only for laboratory research and sponsor-held IND studies; for an IND study, the IND number, sponsor details and protocol are required before any supply. Establishment registration is not product approval, and ExaVeyra makes no claim that any cell or tissue product is safe or effective for any condition. Whether a study’s use complies with state law and the investigator’s scope of practice is a determination for the sponsor, the investigator and their counsel. ExaVeyra Sciences is a supplier: it does not provide medical care, does not consult with patients and takes no part in clinical decisions.
Compounded preparations. Compounded preparations are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before they are dispensed. Each preparation is compounded and dispensed by our 503A pharmacy partner, licensed by its state Board of Pharmacy, on a patient-specific prescription from a licensed prescriber; ExaVeyra Sciences does not compound, dispense or prescribe. ExaVeyra makes no claim that any preparation is safe or effective for any condition. Availability depends on the pharmacy’s license in the destination state and on whether the substance may be compounded under federal and state law. Prescribing, patient selection and scope of practice are the responsibility of the licensed prescriber. ExaVeyra Sciences is a supplier: it does not provide medical care, does not consult with patients and takes no part in clinical decisions.
Medical devices. Medical devices are sold for the intended use stated in each manufacturer’s labeling, with its instructions for use. The CuraCator is an FDA-listed Class I device (21 CFR 880.6430), open to any buyer; listing is neither approval nor clearance, and it does not extend to any product applied with the device. Which product is applied, and how, is the user’s decision. ExaVeyra Sciences is a supplier: it does not provide medical care, does not consult with patients and takes no part in clinical decisions.
Musculoskeletal biologics are a registered, evolving research field
Investigators worldwide have registered studies of exosomes, extracellular vesicles, secretomes and perinatal tissue across musculoskeletal research. Most are early phase, small and focused on safety, which is how a new class of biologic enters clinical research.
In the United States an unapproved biologic is studied under an investigational new drug application (IND) held by the study sponsor. The registry marks those studies as FDA-regulated drug studies; 4 of the studies below carry that flag, one of them run from Florida.
- registered studies listed
- 15
- US FDA-regulated drug studies
- 4
- in Phase 1 or earlier
- 8
| Study | Material studied | Area studied | Phase, participants | Status |
|---|---|---|---|---|
| NCT05211986Immunis, Inc., United StatesFDA-regulated drug study | Stem cell secretome (IMM01-STEM) | Muscle atrophy with knee osteoarthritis | Phase 1/2, 13 participants | Completed |
| NCT07111325Shanghai Sixth People’s Hospital, China | iPSC-derived extracellular vesicles | Lateral epicondylitis | Phase 1/2, 24 participants | Recruiting |
| NCT05261360Eskisehir Osmangazi University, Türkiye | Synovial fluid MSC-derived exosomes | Degenerative meniscal injury | Phase 2, 30 participants | Status not updated |
| NCT06463132Rion Inc., United StatesFDA-regulated drug study | Platelet-derived purified exosome product, alone and with hyaluronic acid | Knee osteoarthritis | Phase 1b, 24 participants | Status not updated |
| NCT06713902IRCCS Ospedale Galeazzi-Sant’Ambrogio, Italy | Extracellular vesicles in a fibrin gel | Cartilage lesions | Phase not stated, 51 participants | Recruiting |
| NCT04849429Dr. Himanshu Bansal Foundation, India | Autologous PRP enriched with exosomes | Degenerative disc disease with chronic low back pain | Phase 1, 30 participants | Completed |
| NCT06361485R3 Stem Cell, United StatesFDA-regulated drug study | Umbilical cord Wharton’s jelly allograft | Lumbar pain | Phase 1, 100 participants | Recruiting |
| NCT07587047Adia Med of Winter Park, United States (Florida)FDA-regulated drug study | Umbilical cord blood-derived cells and exosomes | Chronic mechanical lower back pain | Phase 1, 100 participants | Recruiting |
| NCT06937528University of Jordan, Jordan | Extracellular vesicles, dose-finding | Advanced knee osteoarthrosis | Phase 1, 50 participants | Recruiting |
| NCT06431152Universidad de los Andes, Chile | Umbilical cord MSC small EVs, dose escalation | Knee osteoarthritis | Phase early 1, 12 participants | Status not updated |
| NCT05060107Francisco Espinoza (ExoOA-1) | MSC-derived small EVs | Moderate knee osteoarthritis | Phase 1, 10 participants | Status not updated |
| NCT06466850Isfahan University of Medical Sciences, Iran | Allogeneic MSC-derived exosomes | Knee osteoarthritis | Phase not stated, 20 participants | Recruiting |
| NCT06688318National Research and Innovation Agency (BRIN), Indonesia | Umbilical cord MSC conditioned medium (secretome) | Knee osteoarthritis | Phase 1/2, 11 participants | Active, not recruiting |
| NCT07787923Beijing Jishuitan Hospital, China | MSC-derived exosomes, dose escalation | Non-traumatic avascular necrosis of the femoral head | Phase early 1, 15 participants | Not yet recruiting |
| NCT05520125Institute of Biophysics and Cell Engineering, Belarus | MSCs enriched with extracellular vesicles | Segmental bone defects | Phase 1/2, 20 participants | Status not updated |
Source: ClinicalTrials.gov, records read on October 4, 2026. Listing a study describes what was registered; it reports no result and makes no claim about any product.
How ExaVeyra supports this research
For laboratory research and sponsor-held IND studies, ExaVeyra supplies exosome material, Wharton’s jelly material and NeoScientifix MSC products, subject to each manufacturer’s authorization, with lot documentation, chain of custody and dry-ice cold chain. Wharton’s jelly and MSC material is supplied for those purposes only, and for an IND study the IND number, sponsor details and protocol are required before any supply. ExaVeyra does not sponsor or hold an IND.
The IND and clinical-trial guideBefore a Sports Medicine Practice Joins a Biologic Study: What to Check
Ask who holds the IND
In the United States an unapproved biologic is studied under an investigational new drug application held by the sponsor. Confirm the sponsor, the IND status and the protocol version before any material is ordered for the site.
Match the material to the protocol
The protocol names the investigational product, its source and its lot criteria. Material from a different source or manufacturer is a different product for the study, so the supplier should confirm the manufacturer’s authorization for that protocol.
Read the certificate by method, not by number
Particle counts and identity markers mean little without the method behind them. Ask for the characterization method and confirm it is the same across every lot the study will use.
Plan receipt and storage before the first shipment
Biologics arrive frozen on dry ice. The site needs a receiving log, a freezer at the manufacturer’s stated temperature and a way to file the shipment’s temperature record with the lot.
What Sports Medicine Accounts Order
Research material requires the manufacturer’s authorization for the study, compounded preparations require a patient-specific prescription, and every line requires an NPI-verified account.
IND and Clinical Trial Supply
Exosome material, Wharton’s jelly and MSC products for laboratory research and sponsor-held IND studies, with lot documentation for the study file.
Topical Exosome Material
For practices that also run an aesthetic service, applied topically to intact or healed skin. It ships frozen from the manufacturing facility, and its certificate is available before you order.
503A Compounded Preparations
Dispensed by our licensed pharmacy partner in Texas when a prescriber writes for an identified patient and the substance may be compounded. Formulary access follows NPI verification.
Why Sports Medicine Practices Order Through ExaVeyra
Research Supply Coordinated With the Manufacturer
Study material runs under each manufacturer’s authorization. We coordinate it with the sponsor and the manufacturer before the first shipment.
A Chemist Reads the Certificates
Each lot’s certificate and characterization method is reviewed before it reaches your study team.
Cold Chain With a Record
Every biologic shipment travels on dry ice with a continuous temperature record for the study file.
Shockwave Units on the Same Account
PhysioPRO shockwave units are available to licensed practices through the account that handles your research and prescription supply.
Freight Planned With You
Shockwave units travel as tracked freight, and our logistics team confirms lead times before you schedule installation.
Prescriptions Filled by a Licensed Pharmacy
Compounded preparations are dispensed by our partner pharmacy, licensed by the Texas State Board of Pharmacy, against a prescription written by your own prescriber.
Questions from Sports Medicine Practices
Can a sports medicine practice source biologic material for an IND study?+
Yes, subject to each manufacturer’s authorization for the study. For laboratory research and sponsor-held IND studies ExaVeyra supplies exosome material, Wharton’s jelly material and MSC products from an FDA-registered tissue bank, with a certificate of analysis available on request for each lot. For an IND study, the IND number, sponsor details and protocol are required before any supply. ExaVeyra does not sponsor or hold an IND.
What registered research covers musculoskeletal biologics?+
ClinicalTrials.gov lists early-phase studies of extracellular vesicles, exosomes and stem cell secretomes in musculoskeletal research, several of them in sports-related settings. The table on this page gives each study’s phase, size, sponsor and status.
Is exosome material available for in-office sports medicine use?+
Exosome material is supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research. No exosome product is FDA-approved for any use, and outside an IND the material is supplied only for topical aesthetic use.
Which devices does ExaVeyra supply to sports medicine practices?+
PhysioPRO extracorporeal shockwave units, sold to licensed practices for the intended use in the manufacturer’s labeling, with the manufacturer’s documentation sent for review before you order.
How are compounded preparations supplied?+
Compounded preparations are dispensed by our 503A pharmacy partner on a patient-specific prescription, where the pharmacy holds a license for the destination state, and availability depends on whether the substance may be compounded under federal and state law.
Image credits
- Photo 1Cansu Hangül, Pexels, Pexels License. ↩
- Photo 2Sincerely Media, Unsplash, Unsplash License. ↩
- Photo 3Danik Prihodko, Pexels, Pexels License. ↩